Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes

NCT02593123 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT02593123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02593123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
Lead sponsor
Virginia Commonwealth University
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2015
Completion date
March 18, 2022
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hodgkin's lymphoma, leukemia, lymphoid leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloma, non hodgkin lymphoma, recurrent acute myeloid leukemia, adult, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma